Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALGS 
Aligos Therapeutics Inc (ALGS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ALGS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $80.25
1 Year Target Price $80.25
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 82.07% | Avg. Invested days 58 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.90M USD | Price to earnings Ratio - | 1Y Target Price 80.25 |
Price to earnings Ratio - | 1Y Target Price 80.25 | ||
Volume (30-day avg) 3 | Beta 2.8 | 52 Weeks Range 3.76 - 46.80 | Updated Date 09/15/2025 |
52 Weeks Range 3.76 - 46.80 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1924.04% |
Management Effectiveness
Return on Assets (TTM) -40.3% | Return on Equity (TTM) -87.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -45162986 | Price to Sales(TTM) 22.34 |
Enterprise Value -45162986 | Price to Sales(TTM) 22.34 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 6151370 | Shares Floating 3001994 |
Shares Outstanding 6151370 | Shares Floating 3001994 | ||
Percent Insiders 10.37 | Percent Institutions 54.14 |
Upturn AI SWOT
Aligos Therapeutics Inc
Company Overview
History and Background
Aligos Therapeutics, Inc. (ALGS) is a biopharmaceutical company focused on developing novel therapies to address liver diseases with high unmet medical need. Founded in 2018, it emerged from research efforts aimed at developing treatments for chronic hepatitis B and other liver conditions. Significant milestones include progressing multiple drug candidates into clinical trials and securing partnerships for technology development and funding. Aligos continues to focus on advancing its pipeline of therapeutics targeting HBV and NASH.
Core Business Areas
- Hepatitis B Virus (HBV) Programs: Developing multiple drug candidates targeting different stages of the HBV lifecycle to achieve functional cure.
- Nonalcoholic Steatohepatitis (NASH) Programs: Developing therapeutics to treat NASH, a chronic liver disease, through various mechanisms of action.
Leadership and Structure
Lawrence M Blatt, Ph.D., MBA is the Chairman and CEO. The company has a management team with experience in virology, drug development, and business operations. It operates with a structure typical of a clinical-stage biopharmaceutical company, with departments focused on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- ALG-010133: An antisense oligonucleotide (ASO) designed to reduce hepatitis B surface antigen (HBsAg). Currently in clinical development. Market share is not currently applicable as the drug has not yet been approved or generating revenue. Key competitors in HBV treatment development include Gilead Sciences (GILD), Vir Biotechnology (VIR), and Assembly Biosciences (ASMB).
- ALG-020572: An S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPu2122) designed to directly block HBsAg release. Currently in clinical development. Market share is not currently applicable as the drug has not yet been approved or generating revenue. Key competitors in HBV treatment development include Gilead Sciences (GILD), Vir Biotechnology (VIR), and Assembly Biosciences (ASMB).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, characterized by high R&D costs, regulatory hurdles, and patent protection challenges. The liver disease treatment market is experiencing growth due to increasing prevalence of conditions like HBV and NASH.
Positioning
Aligos is positioned as a clinical-stage company focusing on innovative approaches to HBV and NASH treatment. Their competitive advantage lies in their novel mechanisms of action and the potential to achieve functional cures for HBV.
Total Addressable Market (TAM)
The HBV and NASH markets are estimated to reach billions of dollars. Aligos is aiming to capture a portion of this TAM with its pipeline. The HBV market alone is estimated to be over $3 billion, and the NASH market even larger.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting HBV and NASH
- Experienced management team
- Strong focus on innovative research
- Intellectual property portfolio
Weaknesses
- Limited financial resources as a clinical-stage company
- Dependence on clinical trial success
- High R&D costs and regulatory risks
- No currently marketed products
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new liver disease indications
- Regulatory approval of lead drug candidates
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory delays or rejection
- Patent challenges
Competitors and Market Share
Key Competitors
- GILD
- VIR
- ASMB
Competitive Landscape
Aligos faces competition from established pharmaceutical companies with greater resources and experience. Their advantage lies in their novel approaches and potential for breakthrough therapies, but they face the challenges of a clinical-stage company.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the expansion of the pipeline and progression of drug candidates through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and potential partnerships. Analyst estimates vary but generally reflect optimism based on the potential of the pipeline.
Recent Initiatives: Recent strategic initiatives include advancing lead drug candidates into later-stage clinical trials and exploring partnerships for technology development.
Summary
Aligos Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing novel therapies for HBV and NASH. Their pipeline holds promise, but the company is highly dependent on positive clinical trial outcomes and faces stiff competition. It is actively pursuing various clinical trials and needs to maintain a strong cash flow to keep pursuing its products. Aligos faces the standard risks associated with biotech development, clinical trial failure, regulatory challenges, and competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Aligos Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary based on the source. Investing in biopharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aligos Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-10-16 | CEO, President & Chairman of the Board Dr. Lawrence M. Blatt MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 70 | Website https://www.aligos.com |
Full time employees 70 | Website https://www.aligos.com | ||
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.